Fidelity Investments
INDV icon

Fidelity Investments’s Indivior Pharmaceuticals INDV Stock Holding History

Fidelity Investments’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.1M Buy
527,714
+31,074
+6% +$1.03M ﹤0.01% 1861
2025
Q4 		$17.8M Buy
496,640
+427,187
+615% +$13M ﹤0.01% 1817
2025
Q3 		$1.67M Buy
69,453
+69,143
+22,304% +$1.45M ﹤0.01% 2607
2025
Q2 		$4.61K Buy
+310
New +$3.61K ﹤0.01% 4726
2025
Q1 		– Sell
-205
Closed -$2.55K – 5511
2024
Q4 		$2.55K Sell
205
-355
-63% -$3.65K ﹤0.01% 4781
2024
Q3 		$5.5K Sell
560
-6,538,174
-100% -$76.6M ﹤0.01% 4602
2024
Q2 		$102M Buy
6,538,734
+311,919
+5% +$5.63M 0.01% 1029
2024
Q1 		$133M Buy
6,226,815
+1,122,031
+22% +$21.1M 0.01% 950
2023
Q4 		$77.1M Sell
5,104,784
-393,303
-7% -$6.98M 0.01% 1117
2023
Q3 		$119M Buy
5,498,087
+1,915,980
+53% +$43.7M 0.01% 897
2023
Q2 		$82.9M Buy
+3,582,107
New +$82.1M 0.01% 1075

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments's INDV Position: Q1 2026 in Review

Fidelity Investments increased its Indivior Pharmaceuticals (INDV) stake by 6.3% in Q1 2026, buying an estimated $1.03M and bringing the position to 527,714 shares worth $16.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1861.

Fidelity Investments first reported a position in INDV in Q2 2023 and has held it in 11 quarters since. The position peaked at $133M in Q1 2024. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Fidelity Investments held 527,714 shares of Indivior Pharmaceuticals worth $16.1M as of Q1 2026.
  • Fidelity Investments bought 31,074 Indivior Pharmaceuticals shares in Q1 2026, an estimated $1.03M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #1861 holding.
  • Fidelity Investments first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
  • Fidelity Investments's Indivior Pharmaceuticals position peaked at $133M in Q1 2024.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.